- Home
- WRAP vs MDXH Comparison
WRAP vs MDXH Comparison
Compare WRAP & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WRAP | MDXH |
|---|---|---|
| Founded | 2016 | 2003 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Ordnance And Accessories | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 111.3M | 167.8M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | WRAP | MDXH |
|---|---|---|
| Price | $2.42 | $3.52 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $7.67 |
| AVG Volume (30 Days) | ★ 507.0K | 118.6K |
| Earning Date | 11-12-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $4,133,000.00 | ★ $103,069,000.00 |
| Revenue This Year | N/A | $23.34 |
| Revenue Next Year | N/A | $22.98 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 21.68 |
| 52 Week Low | $1.20 | $1.35 |
| 52 Week High | $3.00 | $5.33 |
Technical Indicators
Market Signals| Indicator | WRAP | MDXH |
|---|---|---|
| Relative Strength Index (RSI) | 52.20 | 49.72 |
| Support Level | $2.09 | $3.20 |
| Resistance Level | $2.36 | $3.58 |
| Average True Range (ATR) | 0.20 | 0.18 |
| MACD | -0.00 | 0.05 |
| Stochastic Oscillator | 35.70 | 82.29 |
Price Performance
Historical ComparisonAbout WRAP Wrap Technologies Inc.
Wrap Technologies Inc is a public safety technology and services company that delivers safe and effective policing solutions to law enforcement and security personnel worldwide. The firm develops policing solutions to law enforcement and security personnel. Its BolaWRAP 150 Remote Restraint device is a patented, hand-held tool that discharges a Kevlar cord to restrain noncompliant individuals from a range of 10-25 feet. The group operates in the Americas, Europe, the Middle East, Africa and the Asia Pacific.
About MDXH MDxHealth SA
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.